These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 34823075

  • 1. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
    Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev S.
    Ann Diagn Pathol; 2022 Feb; 56():151860. PubMed ID: 34823075
    [Abstract] [Full Text] [Related]

  • 2. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Feb; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 3. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 5. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [Abstract] [Full Text] [Related]

  • 6. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
    Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME.
    Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):663-8. PubMed ID: 24897074
    [Abstract] [Full Text] [Related]

  • 7. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
    Pizzi M, Gergis U, Chaviano F, Orazi A.
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
    [Abstract] [Full Text] [Related]

  • 8. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
    Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, von Hünerbein N, Kvasnicka HM, Thiele J, Kreipe HH, Büsche G.
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
    [Abstract] [Full Text] [Related]

  • 9. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B, Diral E, Donsante S, Di Marzo N, Mottadelli F, Cardinale L, Dander E, Isimbaldi G, Pioltelli P, Biondi A, Riminucci M, D'Amico G, Elli EM, Pievani A, Serafini M.
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [Abstract] [Full Text] [Related]

  • 10. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
    Palova M, Szotkowski T, Hlusi A, Indrak K, Navratilova J, Divoka M, Papajik T.
    Neoplasma; 2018 Jan; 65(2):296-303. PubMed ID: 29534592
    [Abstract] [Full Text] [Related]

  • 11. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
    Stein BL, Williams DM, Rogers O, Isaacs MA, Spivak JL, Moliterno AR.
    Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
    [Abstract] [Full Text] [Related]

  • 12. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 13. GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
    Lally J, Boasman K, Brown L, Martinelli V, Cappuccio I, Sovani V, Marinaccio C, Crispino JD, Graham C, Rinaldi C.
    J Thromb Haemost; 2019 Jun; 17(6):896-900. PubMed ID: 30889303
    [Abstract] [Full Text] [Related]

  • 14. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N, Subramanian PG, Kodgule R, Raval G, Joshi S, Chaudhary S, Mascarenhas R, Tembhare P, Gujral S, Patkar N.
    Indian J Pathol Microbiol; 2018 Jun; 61(2):209-213. PubMed ID: 29676359
    [Abstract] [Full Text] [Related]

  • 15. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [Abstract] [Full Text] [Related]

  • 16. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
    Guy A, Bidet A, Ling C, Caumont C, Boureau L, Viallard JF, Parrens M.
    Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
    [Abstract] [Full Text] [Related]

  • 17. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.
    Pizzi M, Silver RT, Barel A, Orazi A.
    Mod Pathol; 2015 Oct; 28(10):1315-23. PubMed ID: 26271725
    [Abstract] [Full Text] [Related]

  • 18. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.
    Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
    [Abstract] [Full Text] [Related]

  • 19. Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-β1 and Cxcl12 pathways.
    Dutta A, Hutchison RE, Mohi G.
    Blood; 2017 Aug 17; 130(7):920-932. PubMed ID: 28637665
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
    Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura-Inoue T, Kiyoi H.
    Intern Med; 2020 Aug 17; 59(16):1947-1956. PubMed ID: 32801269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.